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ABSTRACT
Background Risk factors for severe COVID- 19 include 
older age, male sex, obesity, black or Asian ethnicity and 
underlying medical conditions. Whether these factors 
also influence susceptibility to developing COVID- 19 is 
uncertain.
Methods We undertook a prospective, population- 
based cohort study (COVIDENCE UK) from 1 May 2020 
to 5 February 2021. Baseline information on potential 
risk factors was captured by an online questionnaire. 
Monthly follow- up questionnaires captured incident 
COVID- 19. We used logistic regression models to 
estimate multivariable- adjusted ORs (aORs) for 
associations between potential risk factors and odds of 
COVID- 19.
Results We recorded 446 incident cases of COVID- 19 
in 15 227 participants (2.9%). Increased odds of 
developing COVID- 19 were independently associated 
with Asian/Asian British versus white ethnicity (aOR 
2.28, 95% CI 1.33 to 3.91), household overcrowding 
(aOR per additional 0.5 people/bedroom 1.26, 1.11 to 
1.43), any versus no visits to/from other households 
in previous week (aOR 1.31, 1.06 to 1.62), number of 
visits to indoor public places (aOR per extra visit per 
week 1.05, 1.02 to 1.09), frontline occupation excluding 
health/social care versus no frontline occupation (aOR 
1.49, 1.12 to 1.98) and raised body mass index (BMI) 
(aOR 1.50 (1.19 to 1.89) for BMI 25.0–30.0 kg/m2 
and 1.39 (1.06 to 1.84) for BMI >30.0 kg/m2 versus 
BMI <25.0 kg/m2). Atopic disease was independently 
associated with decreased odds (aOR 0.75, 0.59 to 
0.97). No independent associations were seen for age, 
sex, other medical conditions, diet or micronutrient 
supplement use.
Conclusions After rigorous adjustment for factors 
influencing exposure to SARS- CoV- 2, Asian/Asian British 
ethnicity and raised BMI were associated with increased 
odds of developing COVID- 19, while atopic disease was 
associated with decreased odds.
Trial registration number  ClinicalTrials. gov Registry 
(NCT04330599).
INTRODUCTION
COVID- 19 has taken a heavy toll on the health 
of populations globally.1–3 Risk factors for severe 
and fatal disease are well recognised, and include 
male sex, black or Asian ethnic origin, obesity, 
deprivation and a range of comorbidities including 
diabetes mellitus, cardiovascular disease, COPD 
and hypertension.4 5 Characterisation of risks for 
milder disease has been relatively neglected, but is 
important, both from a public health perspective 
(since it drives transmission to individuals at risk 
of severe disease), and from a biological perspec-
tive (since understanding susceptibility factors can 
provide insights into pathogenesis).
There is growing evidence from population- based 
studies to suggest that at least some risk factors for 
Key messages
What is the key question?
 ► How do demographic, socioeconomic, lifestyle, 
dietary, pharmacological and comorbidity 
factors relate to the risk of developing 
COVID- 19 in the general adult population of 
the UK?
What is the bottom line?
 ► After rigorous adjustment for factors 
influencing exposure to SARS- CoV- 2, Asian/
Asian British ethnicity and raised body mass 
index were associated with increased risk of 
developing COVID- 19, while atopic disease was 
associated with decreased risk; no associations 
were seen for age, sex or other underlying 
medical conditions.
Why read on?
 ► This large, population- based prospective study 
shows that there is limited overlap between risk 
factors for developing COVID- 19 versus those 
for intensive care unit admission and death as 
reported in hospitalised cohorts.
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developing COVID- 19—irrespective of severity—may be distinct 
from those which predispose to disease at the most severe end of 
the spectrum. For example, population- based studies in both the 
USA and the UK have reported that risk of COVID- 19 is higher 
in younger versus older adults,6 a finding supported by serology 
studies in the UK and Switzerland reporting higher prevalence 
of antibodies to SARS- CoV- 2 in younger versus older adults.7 8 
Again, in contrast to studies reporting that diabetes, heart disease 
and hypertension are risk factors for severe disease, the presence 
of pre- existing health conditions has been reported to associate 
with decreased, rather than increased, risk of SARS- CoV- 2 sero-
positivity in a population- based study conducted in the UK.7
These apparently paradoxical associations are potentially 
attributable to changes in behaviour in response to the pandemic, 
whereby people at greater risk of severe disease because of older 
age or presence of comorbidities may reduce social contact and 
visits to indoor public places in order to reduce their exposure 
to SARS- CoV- 2. However, to our knowledge, studies to investi-
gate whether behaviours influencing risk of such exposure might 
partly explain associations between older age, presence of comor-
bidities and lower risk of developing COVID- 19 are lacking. 
Such studies could potentially shed light on other controversies 
relating to risk factors for developing COVID- 19, such as the 
extent to which ethnic differences in disease susceptibility can 
be explained by behavioural, occupational and socioeconomic 
factors,9 and whether lifestyle, diet and use of micronutrient 
supplements may influence risk of developing COVID- 19.10 11
In order to address this knowledge gap, we established a 
new longitudinal study (COVIDENCE UK) at the start of the 
pandemic, with the specific aim of capturing detailed informa-
tion on a very wide range of potential risk factors for COVID- 
19. Sufficient incident cases of test- confirmed COVID- 19 have 
now accumulated to allow us to evaluate how a comprehensive 
panel of demographic, socioeconomic, lifestyle, dietary, pharma-
cological and comorbidity factors relate to the risk of developing 
COVID- 19.
METHODS
Study design, setting and participants
COVIDENCE UK is a prospective longitudinal population- based 
observational study of coronavirus disease in the UK population 
( www. qmul. ac. uk/ covidence). Inclusion criteria are age 16 years 
or more and residence in the UK at the point of enrolment; there 
are no exclusion criteria. Participants were invited via a national 
media campaign to complete an online baseline questionnaire to 
capture information on potential symptoms of COVID- 19 expe-
rienced since 1 February 2020, results of any COVID- 19 tests 
and details of a wide range of potential risk factors for COVID- 
19, as described below. Follow- up questionnaires were admin-
istered at monthly intervals to capture incident test- confirmed 
COVID- 19 as well as potential symptoms of COVID- 19. The 
study was launched on 1 May 2020, and this paper reports find-
ings of analysis of data collected up to 5 February 2021.
Outcomes
The primary outcome was incidence of test- confirmed COVID- 
19, as defined by a self- reported positive result from PCR or 
lateral flow testing of eluate from a nose or throat swab for SARS- 
CoV- 2. Those who were not tested were assumed to be test nega-
tive. The secondary outcome was incidence of symptom- defined 
probable COVID- 19, with casehood defined using the algorithm 
described by Menni et al,12 based on age, sex and self- reported 
loss of smell/taste, significant/severe persistent cough, severe 
fatigue and skipped meals (see online supplemental appendix for 
further details). This outcome was included in order to address 
potential underascertainment of COVID- 19 arising from use of 
test- confirmed COVID- 19 as an outcome measure, which would 
not have captured episodes where testing was not done, poten-
tially introducing collider bias.13 Test- confirmed COVID- 19 and 
symptom- defined probable COVID- 19 were analysed as sepa-
rate outcomes (ie, they were not combined). In order to mini-
mise the potential for reverse causality to explain associations 
observed, outcomes occurring within 30 days of enrolment were 
excluded. At enrolment, participants were asked to provide 
details of potential symptoms of COVID- 19 experienced since 
1 February 2020, and results of any PCR or lateral flow tests 
for SARS- CoV- 2 performed on eluates from nose/throat swabs 
to date.
Independent variables
At enrolment, participants were asked to complete an online 
questionnaire capturing information about their sociodemo-
graphic characteristics, type of occupation, lifestyle, weight, 
height, long- standing medical conditions, medication use, 
vaccination status, diet and supplemental micronutrient intake 
(for baseline questionnaire, see online supplemental table 1). 
Monthly online follow- up questionnaires (online supplemental 
Figure 1 Dose–response relationship between body mass index 
(BMI) (A) and age (B) and risk of incident test- defined COVID- 19 using 
restricted cubic spline analysis. The multivariable models were mutually 
adjusted for all factors presented in table 5.
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table 2) captured incident test- confirmed COVID- 19 and poten-
tial symptoms of COVID- 19.
Sample size and statistical methods
The sample size calculation and full details of statistical methods 
are presented in the online supplemental appendix. Partici-
pants who reported definite COVID- 19 prior to enrolment, or 
who were classified as having had symptom- defined probable 
COVID- 19 prior to enrolment on the basis of self- reported 
symptoms, were excluded from prospective analyses. Logistic 
regression models were used to estimate ORs and 95% CIs for 
potential determinants of COVID- 19 risk, first in a crude model, 
then in minimally adjusted and fully adjusted models. Correction 
for multiple comparisons was not applied, on the grounds that 
we were testing a priori hypotheses for all risk factors inves-
tigated.14 We conducted sensitivity analysis for unmeasured 
Table 1 Selected cohort characteristics
Total
Test- confirmed COVID- 19
No Yes
n (%) 15 227 (86.7) 14 781 (97.1) 446 (2.9)
Age, n (%)
16–29.99 years 576 (3.8) 550 (3.7) 26 (5.8)
30–39.99 years 988 (6.5) 941 (6.4) 47 (10.5)
40–49.99 years 1787 (11.7) 1693 (11.5) 94 (21.1)
50–59.99 years 3361 (22.1) 3226 (21.8) 135 (30.3)
60–69.99 years 5105 (33.5) 5008 (33.9) 97 (21.7)
≥70.00 years 3410 (22.4) 3363 (22.8) 47 (10.5)
Age, years 59.4±13.4 59.5±13.4 53.3±13.2
Sex, n (%)
Female 10 630 (69.8) 10 301 (69.7) 329 (73.8)
Male 4597 (30.2) 4480 (30.3) 117 (26.2)
Ethnicity, n (%)
White 14 449 (94.9) 14 046 (95.0) 403 (90.4)
Mixed/multiple/other 
ethnic groups
401 (2.6) 382 (2.6) 19 (4.3)
South Asian 281 (1.8) 263 (1.8) 18 (4.0)
Black/African/
Caribbean/black British
96 (0.6) 90 (0.6) 6 (1.3)
Country of residence, n (%)
England 13 463 (88.4) 13 052 (88.3) 411 (92.2)
Northern Ireland 294 (1.9) 281 (1.9) 13 (2.9)
Scotland 915 (6.0) 910 (6.2) 5 (1.1)
Wales 555 (3.6) 538 (3.6) 17 (3.8)
Household income sufficient for basic 
needs, n (%)
Yes 14 209 (93.3) 13 793 (93.3) 416 (93.3)
Mostly/sometimes/no 1016 (6.7) 986 (6.7) 30 (6.7)
Housing, n (%)
Owns own home 9326 (61.3) 9137 (61.8) 189 (42.4)
Mortgage 3743 (24.6) 3570 (24.2) 173 (38.8)
Privately renting 1069 (7.0) 1029 (7.0) 40 (9.0)
Renting from council 477 (3.1) 461 (3.1) 16 (3.6)
Others 610 (4.0) 582 (3.9) 28 (6.3)
Number of people per bedroom, n (%)
≤0.50 5836 (38.6) 5738 (39.1) 98 (22.3)
>0.50–0.99 4179 (27.6) 4069 (27.7) 110 (25.0)
1.00–1.99 4766 (31.5) 4553 (31.0) 213 (48.4)
≥2.00 333 (2.2) 314 (2.1) 19 (4.3)
Highest educational level attained, n (%)
Primary/secondary 1649 (10.8) 1598 (10.8) 51 (11.4)
Higher/further (A 
levels)
2233 (14.7) 2164 (14.7) 69 (15.5)
College 6720 (44.2) 6523 (44.2) 197 (44.2)
Postgraduate 4610 (30.3) 4481 (30.3) 129 (28.9)
Occupational status, n (%)
Employed 5349 (35.1) 5091 (34.4) 258 (57.8)
Self- employed 1369 (9.0) 1330 (9.0) 39 (8.7)
Continued
Total
Test- confirmed COVID- 19
No Yes
Retired 6951 (45.6) 6856 (46.4) 95 (21.3)
Furloughed 365 (2.4) 348 (2.4) 17 (3.8)
Unemployed 267 (1.8) 254 (1.7) 13 (2.9)
Other 926 (6.1) 902 (6.1) 24 (5.4)
Frontline worker, n (%)
No 12 474 (82.0) 12 198 (82.6) 276 (61.9)
Other frontline worker 1572 (10.3) 1492 (10.1) 80 (17.9)
Health or social care 
worker
1167 (7.7) 1077 (7.3) 90 (20.2)
Body mass index, n (%)
<25 kg/m2 7431 (48.9) 7254 (49.2) 177 (39.8)
25–30 kg/m2 4829 (31.8) 4661 (31.6) 168 (37.8)
>30 kg/m2 2929 (19.3) 2829 (19.2) 100 (22.5)
Self- reported general health, n (%)
Excellent 3071 (20.2) 2982 (20.2) 89 (20.0)
Very good 6024 (39.6) 5850 (39.6) 174 (39.0)
Good 4048 (26.6) 3928 (26.6) 120 (26.9)
Fair 1633 (10.7) 1581 (10.7) 52 (11.7)
Poor 449 (2.9) 438 (3.0) 11 (2.5)
Tobacco smoking history, n (%)
Never smoker 8529 (56.0) 8282 (56.0) 247 (55.4)
Ex- smoker 5862 (38.5) 5697 (38.5) 165 (37.0)
Current smoker 836 (5.5) 802 (5.4) 34 (7.6)
Alcohol consumption in week prior to questionnaire 
completion, n (%)
None 4271 (28.1) 4152 (28.1) 119 (26.7)
1–7 units 5406 (35.5) 5244 (35.5) 162 (36.3)
8–14 units 2961 (19.4) 2876 (19.5) 85 (19.1)
15–21 units 1417 (9.3) 1366 (9.2) 51 (11.4)
22–28 units 657 (4.3) 640 (4.3) 17 (3.8)
>28 units 513 (3.4) 501 (3.4) 12 (2.7)
COVID- 19 vaccine during follow- up, n (%)
No 14 529 (85.7) 12 675 (85.8) 365 (81.8)
Yes 2416 (14.3) 2106 (14.2) 81 (18.2)
Table 1 Continued
3Holt H, et al. Thorax 2021;0:1–13. doi:10.1136/thoraxjnl-2021-217487
Respiratory infection
Table 2 Sociodemographic, occupational and lifestyle factors and risk of test- confirmed COVID- 19: crude and minimally adjusted ORs
Number (%) with incident 
test- confirmed COVID- 19 Total number Crude OR (95% CI)
Minimally adjusted OR 
(95% CI)*
Age, years 16–29.99 26 (4.5) 15 227 1.00 1.00
30–39.99 47 (4.8) 1.06 (0.65 to 1.73) 1.08 (0.65 to 1.78)
40–49.99 94 (5.3) 1.17 (0.75 to 1.83) 1.24 (0.79 to 1.95)
50–59.99 135 (4.0) 0.89 (0.58 to 1.36) 0.96 (0.62 to 1.49)
60–69.99 97 (1.9) 0.41 (0.26 to 0.64) 0.49 (0.31 to 0.77)
≥70.00 47 (1.4) 0.30 (0.18 to 0.48) 0.39 (0.24 to 0.64)
Sex Female 329 (3.1) 15 227 1.00 1.00
Male 117 (2.5) 0.82 (0.66 to 1.01) 1.08 (0.86 to 1.34)
Ethnicity Asian/Asian British 18 (6.4) 15 227 2.39 (1.46 to 3.88) 1.99 (1.20 to 3.30)
Black/African/Caribbean/black British 6 (6.3) 2.32 (1.01 to 5.34) 1.98 (0.84 to 4.65)
Mixed/multiple/other ethnic groups 19 (4.7) 1.73 (1.08 to 2.78) 1.40 (0.86 to 2.28)
White 403 (2.8) 1.00 1.00
Highest educational level attained Primary/secondary 51 (3.1) 15 212 1.00 1.00
Higher/further (A levels) 69 (3.1) 1.00 (0.69 to 1.44) 0.86 (0.59 to 1.25)
College 197 (2.9) 0.95 (0.69 to 1.29) 0.75 (0.54 to 1.03)
Postgraduate 129 (2.8) 0.90 (0.65 to 1.25) 0.62 (0.44 to 0.87)
Index of Multiple Deprivation rank, 
quartiles
Q1 (most deprived) 131 (3.6) 15 152 1.30 (1.01 to 1.69) 1.22 (0.93 to 1.60)
Q2 108 (2.8) 1.02 (0.78 to 1.34) 0.97 (0.73 to 1.28)
Q3 97 (2.5) 0.90 (0.68 to 1.19) 0.89 (0.67 to 1.19)
Q4 (least deprived) 107 (2.8) 1.00 1.00
Household income sufficient for basic 
needs
Yes 416 (2.9) 15 225 1.00 1.00
Mostly/sometimes/no 30 (3.0) 1.01 (0.69 to 1.47) 0.85 (0.58 to 1.25)
Claiming universal credit No 425 (2.9) 15 178 1.00 1.00
Yes 19 (4.7) 1.65 (1.03 to 2.64) 1.25 (0.77 to 2.03)
Housing Owns own home 189 (2.0) 15 225 1.00 1.00
Mortgage 173 (4.6) 2.34 (1.90 to 2.89) 1.34 (1.04 to 1.74)
Privately renting 40 (3.7) 1.88 (1.33 to 2.66) 1.17 (0.79 to 1.73)
Renting from council 16 (3.4) 1.68 (1.00 to 2.82) 1.20 (0.70 to 2.07)
Others 28 (4.6) 2.33 (1.55 to 3.49) 1.54 (0.95 to 2.49)
Frontline worker No 276 (2.2) 15 213 1.00 1.00
Health or social care worker 90 (7.7) 3.69 (2.89 to 4.72) 1.68 (1.28 to 2.21)
Other frontline worker 80 (5.1) 2.37 (1.84 to 3.06) 1.85 (1.42 to 2.42)
Shielding No 423 (3.0) 15 171 1.00 1.00
Yes 23 (2.0) 0.64 (0.42 to 0.98) 0.63 (0.41 to 0.97)
Number of people per bedroom ≥0.50 98 (1.7) 15 114 1.00 1.00
>0.50–0.99 110 (2.6) 1.58 (1.20 to 2.08) 1.34 (1.01 to 1.78)
1–1.99 213 (4.5) 2.74 (2.15 to 3.49) 1.91 (1.46 to 2.50)
≥2.00 19 (5.7) 3.54 (2.14 to 5.87) 2.41 (1.40 to 4.13)
Any visits to/from other households in 
week prior to questionnaire completion
No 202 (2.7) 15 217 1.00 1.00
Yes 244 (3.2) 1.21 (1.00 to 1.46) 1.46 (1.19 to 1.80)
Preschool children (0–4 years old) at 
home with participant
No 416 (2.8) 15 191 1.00 1.00
Yes 30 (5.9) 2.15 (1.47 to 3.15) 1.19 (0.77 to 1.84)
Schoolchildren (5–15 years old) at home 
with participant
No 351 (2.6) 15 182 1.00 1.00
Yes 95 (5.5) 2.18 (1.73 to 2.75) 1.42 (1.08 to 1.87)
Working- age adult (16–64 years old) at 
home with participant
No 117 (1.6) 15 183 1.00 1.00
Yes 329 (4.2) 2.74 (2.21 to 3.39) 1.86 (1.45 to 2.41)
Number of different generations in 
household
Living alone 46 (1.6) 15 227 1.00 1.00
Single generation 230 (2.8) 1.78 (1.29 to 2.45) 1.66 (1.19 to 2.30)
Two generations 164 (4.1) 2.62 (1.88 to 3.64) 2.08 (1.48 to 2.94)
Three generations 6 (5.0) 3.27 (1.37 to 7.83) 2.54 (1.04 to 6.23)
Continued
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confounding by estimating E- values15 using the ‘evalue’ package 
in Stata.16 Two other sensitivity analyses were also performed: 
one excluded participants who received one or more doses of 
COVID- 19 vaccine, and the other excluded those who were 
randomised to receive vitamin D supplementation as part of 
a nested clinical trial that was initiated during follow- up. We 
also performed an exploratory analysis to determine whether 
COVID- 19 risk differed for participants with atopic versus non- 
atopic asthma endotypes; this was conducted on the basis of 
evidence suggesting that decreased expression of ACE2, the gene 
encoding the SARS- CoV- 2 receptor, has been reported in people 
with asthma who have high levels of allergic sensitisation.17
Number (%) with incident 
test- confirmed COVID- 19 Total number Crude OR (95% CI)
Minimally adjusted OR 
(95% CI)*
Cat at home No 344 (2.9) 15 215 1.00 1.00
Yes 102 (3.1) 1.06 (0.85 to 1.33) 0.88 (0.70 to 1.12)
Dog at home No 317 (2.7) 15 215 1.00 1.00
Yes 129 (3.6) 1.33 (1.08 to 1.64) 1.21 (0.97 to 1.50)
Number of public transport journeys in 
week prior to questionnaire completion
0 393 (2.9) 15 175 1.00 1.00
1–5 35 (3.0) 1.02 (0.72 to 1.45) 1.12 (0.78 to 1.61)
≥6 17 (3.7) 1.29 (0.79 to 2.12) 1.37 (0.82 to 2.28)
Travel to work/study in week prior to 
questionnaire completion
No 37 (2.5) 15 042 1.00 1.00
Yes 318 (3.8) 1.54 (1.09 to 2.18) 1.71 (1.20 to 2.44)
Not currently working or studying 88 (1.7) 0.68 (0.46 to 1.00) 1.20 (0.79 to 1.81)
Number of visits to shops and other 
indoor public places in week prior to 
questionnaire completion, quartiles
Q1 33 (1.5) 15 207 1.00 1.00
Q2 151 (3.0) 2.05 (1.40 to 2.99) 2.23 (1.51 to 3.29)
Q3 118 (3.3) 2.25 (1.52 to 3.32) 2.77 (1.85 to 4.14)
Q4 144 (3.2) 2.16 (1.48 to 3.17) 3.38 (2.25 to 5.07)
Tobacco smoking status Never smoker 247 (2.9) 15 227 1.00 1.00
Ex- smoker 165 (2.8) 0.97 (0.80 to 1.19) 1.09 (0.89 to 1.35)
Current smoker 34 (4.1) 1.42 (0.99 to 2.05) 1.24 (0.85 to 1.82)
Regular exposure to environmental 
tobacco smoke at home or in car
No 433 (2.9) 15 226 1.00 1.00
Yes 13 (3.9) 1.35 (0.77 to 2.37) 1.17 (0.66 to 2.09)
Vaping status Never vaper 410 (2.9) 15 185 1.00 1.00
Ex- vaper 16 (3.2) 1.12 (0.67 to 1.86) 0.89 (0.53 to 1.50)
Current vaper 19 (4.0) 1.40 (0.88 to 2.24) 1.04 (0.64 to 1.69)
Alcohol consumption in week prior to 
questionnaire completion, units
None 119 (2.8) 15 225 1.00 1.00
1–7 162 (3.0) 1.08 (0.85 to 1.37) 1.08 (0.85 to 1.38)
8–14 85 (2.9) 1.03 (0.78 to 1.37) 1.07 (0.80 to 1.43)
15–21 51 (3.6) 1.30 (0.93 to 1.82) 1.40 (0.99 to 1.98)
22–28 17 (2.6) 0.93 (0.55 to 1.55) 1.10 (0.65 to 1.87)
>28 12 (2.3) 0.84 (0.46 to 1.52) 0.95 (0.52 to 1.76)
Hours of vigorous physical exercise in 
week prior to questionnaire completion†
0 171 (2.9) 15 176 1.00 1.00
1–3 163 (2.9) 0.98 (0.79 to 1.22) 0.95 (0.75 to 1.18)
≥4 109 (2.9) 0.99 (0.78 to 1.27) 1.03 (0.80 to 1.32)
Hours of light physical exercise in week 
prior to questionnaire completion‡
0–4 189 (3.6) 15 192 1.00 1.00
5–9 140 (2.8) 0.76 (0.61 to 0.95) 0.87 (0.69 to 1.10)
≥10 117 (2.4) 0.64 (0.51 to 0.81) 0.89 (0.70 to 1.14)
Hours of lower impact physical 
activity in week prior to questionnaire 
completion§
0 274 (3.1) 15 176 1.00 1.00
1 88 (3.1) 0.97 (0.76 to 1.24) 0.90 (0.70 to 1.16)
≥2 83 (2.3) 0.73 (0.57 to 0.94) 0.76 (0.59 to 0.98)
Estimated average hours of sleep per 
night in month prior to questionnaire 
completion¶
≤6 41 (3.1) 15 223 1.22 (0.86 to 1.73) 1.15 (0.80 to 1.64)
7 113 (3.1) 1.20 (0.94 to 1.53) 1.24 (0.97 to 1.59)
8 159 (2.6) 1.00 1.00
≥9 133 (3.3) 1.28 (1.02 to 1.62) 1.26 (0.99 to 1.60)
Minimally adjusted ORs (95% CI) with a p value of <0.10 are emboldened.
*Adjusted for age, sex, duration of participation and test frequency.
†Defined as exercise of sufficient intensity to make the participant breathless or to raise their heart rate significantly, such as heavy physical work, strenuous gardening (eg, vigorous digging, landscaping), swimming, 
jogging, aerobics, football, tennis, cycling and gym workout, reported to the nearest hour.
‡Defined as exercise that did not make the participant breathless, such as light gardening, walking, including walking for pleasure or exercise, walking to the shops and walking to work, reported to the nearest hour.
§Defined as exercise to improve flexibility or core strength such as yoga, tai chi or Pilates, reported to the nearest hour.
¶Reported to the nearest hour.
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Table 3 Underlying conditions, medication use, vaccination status and risk of test- confirmed COVID- 19: crude and minimally adjusted ORs
Number (%) with incident 
test- confirmed COVID- 19 Total number Crude OR (95% CI) Minimally adjusted OR (95% CI)*
Underlying conditions
Self- rated general health Excellent 89 (2.9) 15 225 1.00 1.00
Very good 174 (2.9) 1.00 (0.77 to 1.29) 1.06 (0.81 to 1.38)
Good 120 (3.0) 1.02 (0.77 to 1.35) 1.03 (0.77 to 1.37)
Fair 52 (3.2) 1.10 (0.78 to 1.56) 0.99 (0.70 to 1.42)
Poor 11 (2.4) 0.84 (0.45 to 1.59) 0.75 (0.40 to 1.43)
Self- rated anxiety or depression No 316 (2.8) 15 216 1.00 1.00
Yes 130 (3.2) 1.13 (0.92 to 1.39) 0.91 (0.73 to 1.12)
Body mass index, kg/m2 <25 177 (2.4) 15 189 1.00 1.00
25–30 168 (3.5) 1.48 (1.19 to 1.83) 1.58 (1.27 to 1.97)
>30 100 (3.4) 1.45 (1.13 to 1.86) 1.37 (1.06 to 1.77)
Asthma No 384 (3.0) 15 227 1.00 1.00
Yes 62 (2.5) 0.82 (0.62 to 1.07) 0.67 (0.51 to 0.88)
Atopic disease† No 349 (3.1) 15 227 1.00 1.00
Yes 97 (2.5) 0.80 (0.64 to 1.01) 0.65 (0.51 to 0.82)
COPD No 438 (2.9) 15 227 1.00 1.00
Yes 8 (2.5) 0.84 (0.41 to 1.70) 1.14 (0.55 to 2.34)
Diabetic status No diabetes 415 (3.0) 15 206 1.00 1.00
Pre- diabetes 14 (3.1) 1.06 (0.62 to 1.82) 1.38 (0.79 to 2.41)
Type 1 diabetes 3 (2.8) 0.96 (0.30 to 3.02) 0.81 (0.25 to 2.62)
Type 2 diabetes 13 (2.1) 0.70 (0.40 to 1.22) 0.92 (0.52 to 1.62)
Heart disease‡ No 432 (3.0) 15 227 1.00 1.00
Yes 14 (2.4) 0.80 (0.47 to 1.38) 1.28 (0.73 to 2.25)
Arterial disease§ No 431 (3.0) 15 227 1.00 1.00
Yes 15 (1.9) 0.63 (0.38 to 1.07) 0.91 (0.53 to 1.57)
Hypertension No 378 (3.2) 15 227 1.00 1.00
Yes 68 (2.1) 0.64 (0.50 to 0.84) 0.88 (0.67 to 1.17)
Kidney disease No 441 (3.0) 15 227 1.00 1.00
Yes 5 (1.6) 0.54 (0.22 to 1.31) 0.62 (0.25 to 1.52)
Major neurological conditions¶ No 440 (3.0) 15 227 1.00 1.00
Yes 6 (1.5) 0.50 (0.22 to 1.12) 0.62 (0.27 to 1.41)
Cancer Never 410 (3.0) 15 227 1.00 1.00
Past (cured or in remission) 33 (2.6) 0.87 (0.61 to 1.25) 1.12 (0.77 to 1.63)
Present (active treatment in 
progress)
3 (2.2) 0.72 (0.23 to 2.27) 0.89 (0.28 to 2.87)
Immunodeficiency** No 446 (2.9) 15 140 1.00 1.00
Yes 0 (0.0) Not applicable Not applicable
Periodontitis†† No 240 (2.7) 15 227 1.00 1.00
  Yes 129 (3.3) 1.20 (0.96 to 1.49) 1.30 (1.04 to 1.62)
  Missing 77 (3.05) 1.12 (0.86 to 1.45) 1.13 (0.86 to 1.49)
Medications
Statins No 398 (3.2) 15 227 1.00 1.00
Yes 48 (1.8) 0.57 (0.42 to 0.77) 0.93 (0.67 to 1.29)
ACE inhibitors No 415 (3.0) 15 227 1.00 1.00
Yes 31 (2.1) 0.68 (0.47 to 0.99) 0.90 (0.62 to 1.32)
Proton pump inhibitors No 395 (3.0) 15 227 1.00 1.00
Yes 51 (2.4) 0.80 (0.60 to 1.08) 0.88 (0.65 to 1.20)
Inhaled corticosteroids No 410 (3.0) 15 227 1.00 1.00
Yes 36 (2.5) 0.83 (0.59 to 1.18) 0.68 (0.48 to 0.97)
Systemic immunosuppressants No 437 (3.0) 15 227 1.00 1.00
Yes 9 (1.3) 0.43 (0.22 to 0.84) 0.39 (0.20 to 0.77)
Selective serotonin reuptake inhibitors (SSRIs) No 401 (2.8) 15 227 1.00 1.00
Yes 45 (4.2) 1.50 (1.09 to 2.05) 1.19 (0.86 to 1.64)
Continued
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Role of the funding source
Barts Charity and Health Data Research UK had no role in study 
design, data analysis, data interpretation or writing of the report. 
MT, HH and MG had access to raw data. The corresponding 
author had full access to all data in the study and had final 
responsibility for the decision to submit for publication.
RESULTS
Of the 17 558 participants who completed the COVIDENCE 
UK baseline questionnaire on or before 2 November 2020, 
we excluded those who were identified as already having had 
test- confirmed and/or symptom- defined probable COVID- 19 
(n=1477). Of the remaining 16 081 participants, 15 227 
completed at least one subsequent monthly follow- up question-
naire at least 30 days after enrolment and were included in this 
prospective analysis; 14 348 completed the final follow- up ques-
tionnaire on or before 5 February 2021, giving a retention rate 
of 89.2% (online supplemental figure 1). Selected baseline char-
acteristics of participants included in the prospective analysis 
are presented in table 1; their characteristics are compared with 
those who were excluded from this analysis in online supple-
mental table 3. Mean age of those contributing data to prospec-
tive analyses was 59.4 years (range 16.0–94.4 years), 69.8% 
were female and 94.9% identified their ethnic origin as white. 
Number (%) with incident 
test- confirmed COVID- 19 Total number Crude OR (95% CI) Minimally adjusted OR (95% CI)*
Non- SSRI antidepressants No 424 (2.9) 15 227 1.00 1.00
Yes 22 (3.4) 1.19 (0.77 to 1.84) 1.17 (0.75 to 1.83)
Angiotensin receptor blockers No 427 (3.0) 15 227 1.00 1.00
Yes 19 (2.2) 0.74 (0.46 to 1.17) 1.01 (0.62 to 1.63)
Vitamin K antagonists No 444 (2.9) 15 227 1.00 1.00
Yes 2 (1.8) 0.61 (0.15 to 2.46) 0.73 (0.18 to 3.06)
Beta- blockers No 424 (3.0) 15 227 1.00 1.00
Yes 22 (2.0) 0.67 (0.43 to 1.03) 0.91 (0.59 to 1.43)
Thiazides No 437 (3.0) 15 227 1.00 1.00
Yes 9 (1.8) 0.61 (0.31 to 1.19) 0.81 (0.41 to 1.60)
H2- receptor antagonists No 442 (2.9) 15 227 1.00 1.00
Yes 4 (4.6) 1.60 (0.59 to 4.39) 1.36 (0.48 to 3.83)
Calcium channel blockers No 417 (3.0) 15 227 1.00 1.00
Yes 29 (2.0) 0.64 (0.44 to 0.93) 0.91 (0.61 to 1.36)
Inhaled bronchodilators‡‡ No 14 (2.0) 15 227 1.00 1.00
Yes 411 (3.0) 0.84 (0.59 to 1.20) 0.54 (0.31 to 0.94)
Non- steroidal anti- inflammatory drugs No 421 (3.0) 15 227 1.00 1.00
Yes 25 (2.0) 0.66 (0.44 to 0.99) 0.84 (0.55 to 1.28)
Sodium- glucose co- transporter- 2 inhibitors No 444 (2.9) 15 227 1.00 1.00
Yes 2 (2.5) 0.86 (0.21 to 3.51) 0.95 (0.23 to 4.00)
Anti- platelet drugs No 422 (3.0) 15 227 1.00 1.00
Yes 24 (2.5) 0.83 (0.55 to 1.26) 1.29 (0.83 to 1.99)
Sex hormone therapy No 401 (2.8) 15 227 1.00 1.00
Yes 45 (4.0) 1.44 (1.05 to 1.97) 1.19 (0.85 to 1.65)
Paracetamol No 430 (2.9) 15 227 1.00 1.00
Yes 16 (2.5) 0.84 (0.51 to 1.39) 0.89 (0.53 to 1.50)
Metformin No 434 (2.9) 15 227 1.00 1.00
Yes 12 (2.8) 0.94 (0.52 to 1.67) 1.28 (0.71 to 2.31)
Bisphosphonates No 441 (2.9) 15 227 1.00 1.00
Yes 5 (1.9) 0.65 (0.27 to 1.58) 0.76 (0.31 to 1.90)
Vaccinations
BCG- vaccinated No 40 (2.0) 15 197 1.00 1.00
Yes 366 (3.1) 1.55 (1.12 to 2.16) 1.36 (0.97 to 1.90)
Unsure 38 (2.5) 1.23 (0.79 to 1.93) 1.26 (0.80 to 2.00)
MMR- vaccinated No 131 (2.6) 11 451 1.00 1.00
Yes 226 (3.5) 1.38 (1.11 to 1.71) 1.04 (0.81 to 1.32)
Minimally adjusted ORs (95% CI) with a p value of <0.10 are bold.
*Adjusted for age, sex, duration of participation and test frequency.
†Defined by atopic eczema/dermatitis and/or hayfever/allergic rhinitis.
‡Defined as coronary artery disease or heart failure.
§Defined as ischaemic heart disease, peripheral vascular disease or cerebrovascular disease.
¶Defined as stroke, transient ischaemic attack, dementia, Parkinson’s disease, multiple sclerosis or motor neuron disease.
**Defined as HIV, primary immune deficiency or other immunodeficiency.
††Defined as being present if participant answered ‘yes’ to any of the three questions relating to gum disease/dental health listed in online supplemental table 2.
‡‡Defined as β-2 adrenoceptor agonists or anticholinergics.
MMR, measles, mumps and rubella.
Table 3 Continued
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Table 4 Diet, supplemental micronutrient intake and risk of test- confirmed COVID- 19: crude and minimally adjusted ORs
Number (%) with incident test- 
confirmed COVID- 19 Total number Crude OR (95% CI) Minimally adjusted OR (95% CI)*
Diet
Dietary restrictions None 419 (2.9) 15 227 1.00 1.00
Vegetarian† 22 (3.2) 1.11 (0.72 to 1.72) 0.89 (0.57 to 1.40)
Vegan‡ 5 (2.2) 0.75 (0.31 to 1.83) 0.60 (0.24 to 1.49)
Number of portions of fruit, vegetables and salad 
intake per day in week prior to questionnaire 
completion, quartiles
Q1 78 (3.5) 15 188 1.00 1.00
Q2 158 (3.1) 0.88 (0.67 to 1.17) 0.90 (0.68 to 1.20)
Q3 87 (3.0) 0.85 (0.62 to 1.16) 0.89 (0.64 to 1.22)
Q4 120 (2.4) 0.66 (0.49 to 0.88) 0.73 (0.54 to 0.99)
Number of portions of dairy products per day in week 
prior to questionnaire completion
0–1 114 (2.8) 15 183 1.00 1.00
2 142 (3.2) 1.15 (0.90 to 1.48) 1.18 (0.91 to 1.53)
3–5 99 (2.7) 0.96 (0.73 to 1.27) 1.06 (0.80 to 1.41)
≥6 91 (2.9) 1.03 (0.78 to 1.37) 1.24 (0.93 to 1.65)
Total number of portions of fish (oily or white) intake 
in the week prior to questionnaire completion
Q1 94 (3.8) 15 213 1.00 1.00
Q2 79 (3.2) 0.85 (0.63 to 1.15) 0.99 (0.73 to 1.36)
Q3 111 (2.7) 0.71 (0.53 to 0.93) 0.88 (0.66 to 1.18)
Q4 162 (2.6) 0.70 (0.54 to 0.90) 0.95 (0.72 to 1.25)
Portions of oily fish intake in the week prior to 
questionnaire completion
0 210 (3.7) 15 220 1.00 1.00
1 133 (2.7) 0.72 (0.58 to 0.90) 0.86 (0.69 to 1.08)
2 71 (2.4) 0.64 (0.49 to 0.85) 0.80 (0.60 to 1.06)
≥3 32 (2.1) 0.57 (0.39 to 0.83) 0.76 (0.52 to 1.13)
Portions of white fish intake in the week prior to 
questionnaire completion
0 131 (3.3) 15 216 1.00 1.00
1 170 (2.8) 0.83 (0.66 to 1.04) 0.99 (0.78 to 1.26)
2 92 (2.6) 0.76 (0.58 to 1.00) 0.95 (0.72 to 1.26)
≥3 53 (3.3) 0.98 (0.71 to 1.35) 1.16 (0.83 to 1.61)
Number of cups of non- alcoholic fluids per day in the 
week prior to questionnaire completion, quartiles
Q1 104 (3.0) 15 177 1.00 1.00
Q2 75 (2.9) 0.98 (0.73 to 1.32) 1.03 (0.76 to 1.41)
Q3 116 (2.5) 0.84 (0.64 to 1.10) 0.81 (0.62 to 1.07)
Q4 149 (3.4) 1.14 (0.88 to 1.47) 0.99 (0.76 to 1.29)
Micronutrient supplement use
Multivitamin supplement No 331 (2.7) 15 227 1.00 1.00
Yes 115 (3.6) 1.33 (1.07 to 1.65) 1.12 (0.89 to 1.40)
Vitamin A supplement No 445 (2.9) 15 227 1.00 1.00
Yes 1 (1.1) 0.38 (0.05 to 2.73) 0.43 (0.06 to 3.15)
Vitamin C supplement No 397 (2.9) 15 227 1.00 1.00
Yes 49 (3.1) 1.09 (0.80 to 1.47) 1.03 (0.76 to 1.41)
Vitamin D supplement No 305 (3.2) 15 227 1.00 1.00
Yes 141 (2.5) 0.80 (0.65 to 0.98) 0.80 (0.65 to 0.99)
Zinc supplement No 425 (2.9) 15 227 1.00 1.00
Yes 21 (2.8) 0.97 (0.62 to 1.51) 0.93 (0.58 to 1.46)
Iron supplement No 423 (2.9) 15 227 1.00 1.00
Yes 23 (4.6) 1.63 (1.06 to 2.51) 1.27 (0.82 to 1.98)
Probiotic supplement No 426 (3.0) 15 227 1.00 1.00
Yes 20 (2.2) 0.72 (0.46 to 1.13) 0.69 (0.44 to 1.10)
Fish oil, krill oil or other omega- 3 supplements No 400 (3.0) 15 227 1.00 1.00
Yes 46 (2.7) 0.91 (0.67 to 1.25) 0.98 (0.71 to 1.35)
Cod liver oil supplement No 409 (2.9) 15 227 1.00 1.00
Yes 37 (3.0) 1.03 (0.73 to 1.45) 1.29 (0.91 to 1.84)
Garlic or garlic powder (allicin) supplement No 439 (2.9) 15 227 1.00 1.00
Yes 7 (2.3) 0.77 (0.36 to 1.63) 0.93 (0.43 to 2.02)
Selenium supplement No 445 (3.0) 15 227 1.00 1.00
Yes 1 (0.6) 0.21 (0.03 to 1.47) 0.20 (0.03 to 1.46)
Minimally adjusted ORs (95% CI) with a p value of <0.10 are emboldened.
*Adjusted for age, sex, duration of participation and test frequency.
†Defined as excluding meat and fish, but not eggs or cow’s milk, from the diet.
‡Defined as excluding meat, fish, eggs and cow’s milk from the diet.
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Table 5 Independent risk factors for test- confirmed COVID- 19: final multivariable model (n=14 556)
Characteristic Categories Fully adjusted OR (95% CI)* P for trend Eest (ECI)
Age, years 16–29.99 1.00 0.08
30–39.99 1.20 (0.68 to 2.12)
40–49.99 1.20 (0.69 to 2.10)
50–59.99 1.12 (0.65 to 1.93)
60–69.99 0.80 (0.44 to 1.44)
≥70.00 0.74 (0.39 to 1.41)
Sex Female 1.00 —
Male 0.97 (0.76 to 1.23)
Ethnicity Asian/Asian British 2.28 (1.33 to 3.91) — 3.99 (1.99)
Black/African/Caribbean/black British 1.84 (0.70 to 4.82)
Mixed/multiple/other ethnic groups 1.53 (0.92 to 2.53)
White 1.00
Highest educational level attained Primary/secondary 1.00 0.08
Higher/further (A levels) 0.90 (0.61 to 1.33)
College 0.82 (0.58 to 1.15)
Postgraduate 0.74 (0.51 to 1.07)
Index of Multiple Deprivation (IMD) rank, quartiles Q1 (most deprived) 1.11 (0.84 to 1.48) 0.44
Q2 0.90 (0.67 to 1.20)
Q3 0.87 (0.65 to 1.16)
Q4 (least deprived) 1.00
Housing Owns own home 1.00 —
Mortgage 1.19 (0.91 to 1.56)
Privately renting 0.96 (0.63 to 1.46)
Renting from council 0.96 (0.53 to 1.74)
Others 1.34 (0.81 to 2.21)
Number of people per bedroom† ≤0.50 1.00 <0.001
>0.50–0.99 1.24 (0.93 to 1.66)
1.00–1.99 1.67 (1.25 to 2.23) 2.73 (1.81)
≥2.00 2.04 (1.15 to 3.60) 3.52 (1.43)
Schoolchildren (aged 5–15 years) at home with participant No 1.00 —
Yes 1.16 (0.86 to 1.56)
Dog at home No 1.00 —
Yes 1.17 (0.93 to 1.47)
Shielding No 1.00 —
Yes 1.04 (0.64 to 1.68)
Any visits to/from other households in week prior to 
questionnaire completion
No 1.00 —
Yes 1.31 (1.06 to 1.62) 1.95 (1.31)
Number of visits to shops and other indoor public places in 
week prior to questionnaire completion‡
Q1 1.00 <0.001
Q2 1.96 (1.29 to 2.98) 3.33 (1.90)
Q3 2.21 (1.43 to 3.43) 3.84 (2.21)
Q4 2.63 (1.69 to 4.10) 4.70 (2.77)
Travel to work/study in week prior to questionnaire completion No 1.00 —
Yes 1.36 (0.93 to 1.99)
Not currently working or studying 1.27 (0.82 to 1.95)
Frontline worker No 1.00 —
Health or social care worker 1.35 (1.00 to 1.82) 2.04 (1.02)
Other frontline worker 1.49 (1.12 to 1.98) 2.34 (1.49)
Number of portions of fruit, vegetables and salad intake per day 
in week prior to questionnaire completion, quartiles
Q1 1.00 0.31
Q2 1.00 (0.75 to 1.35)
Q3 1.04 (0.74 to 1.45)
Q4 0.86 (0.63 to 1.19)
Continued
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The geographical distribution of COVIDENCE UK partici-
pants aligned closely with that of incident COVID- 19 in the UK 
(online supplemental figure 2).
A total of 446 participants experienced at least one episode of 
PCR- confirmed or lateral flow test- confirmed COVID- 19 during 
2 613 921 person- days of follow- up, of whom 32 were hospi-
talised. We calculated crude and minimally adjusted ORs (aORs) 
for associations between risk of test- confirmed COVID- 19 and 
sociodemographic, occupational and lifestyle factors (table 2); 
long- standing conditions, medication use and vaccination status 
(table 3); and diet and supplemental micronutrient intake (table 4). 
After adjustment for age, sex, duration of participation and testing 
frequency (‘minimal adjustment’), the following factors were found 
to associate with increased odds of COVID- 19 with p<0.10: Asian/
Asian British versus white ethnic origin, housing type (paying 
mortgage and ‘other’ vs owning own home), frontline versus 
Characteristic Categories Fully adjusted OR (95% CI)* P for trend Eest (ECI)
Taking vitamin D supplement No 1.00
Yes 0.93 (0.75 to 1.16)
Hours of lower impact physical activity in week prior to 
questionnaire completion§
0 1.00 0.22
1 1.01 (0.78 to 1.31)
≥2 0.83 (0.63 to 1.09)
Estimated average hours of sleep per night in month prior to 
questionnaire completion¶
≤6 1.14 (0.79 to 1.65) 0.31**
7 1.14 (0.88 to 1.48)
8 1.00
≥9 1.29 (1.01 to 1.66) 1.90 (1.11)
Alcohol consumption in week prior to questionnaire completion, 
units
None 1.00 0.39
1–7 1.11 (0.85 to 1.44)
8–14 1.08 (0.79 to 1.47)
15–21 1.45 (1.01 to 2.08)
22–28 1.23 (0.72 to 2.11)
>28 0.83 (0.43 to 1.60)
Body mass index, kg/m2 <25 1.00 0.004
25–30 1.50 (1.19 to 1.89) 2.37 (1.67)
>30 1.39 (1.06 to 1.84) 2.13 (1.31)
Asthma No 1.00 —
Yes 0.82 (0.55 to 1.24)
Atopic disease†† No 1.00 —
Yes 0.75 (0.59 to 0.97) 2.00 (1.21)
Periodontitis‡‡ No 1.00 —
Yes 1.20 (0.95 to 1.52)
Missing 1.03 (0.77 to 1.37)
Systemic immunosuppressants No 1.00 —
Yes 0.47 (0.22 to 0.99) 3.68 (1.11)
Inhaled corticosteroids No 1.00 —
Yes 1.01 (0.55 to 1.84)
Inhaled bronchodilators§§ No 1.00 —
Yes 1.07 (0.61 to 1.88)
BCG- vaccinated No 1.00 —
Yes 1.38 (0.97 to 1.96)
Unsure 1.24 (0.78 to 1.99)
Duration of participation, days 1.00 (1.00 to 1.00) —
Swab test frequency 1.62 (1.52 to 1.72) —
*Adjusted for age, sex, duration of participation, test frequency, ethnicity, highest educational level attained, IMD rank, hours of sleep per night, housing, number of people per bedroom, presence of schoolchildren at 
home, dog at home, shielding, visits to/from other households, visits to shops and other indoor places, travel to work or study, frontline worker status, fruit, vegetable and salad intake, supplemental vitamin D intake, 
low- impact physical activity, alcohol intake, body mass index, history of asthma, history of atopic disease, use of systemic immunosuppressants, use of inhaled corticosteroids, use of inhaled bronchodilators and BCG 
vaccination status.
†Adjusted OR per additional 0.5 people per bedroom 1.26 (95% CI 1.11 to 1.43).
‡Adjusted OR per extra visit per week 1.05 (95% CI 1.02 to 1.09).
§Defined as exercise to improve flexibility or core strength such as yoga, tai chi or Pilates, reported to the nearest hour.
¶Reported to the nearest hour.
**Only applies to sleeping categories below 8 hours.
††Defined by atopic eczema/dermatitis and/or hayfever/allergic rhinitis.
‡‡Defined as being present if participant answered ‘yes’ to any of the three questions relating to gum disease/dental health listed in online supplemental table 2.
§§Defined as β-2 adrenoceptor agonists or anticholinergics.
ECI, E- value for 95% CI; Eest, E- value for point estimate.
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non- frontline worker status, household overcrowding (>0.5 vs 
≤0.5 people per bedroom), any visit versus no visits to/from other 
households in the previous week, presence versus absence of school-
children and working- age adults in the household, living with others 
versus living alone, periodontitis, having versus not having a dog at 
home, any versus no travel to work or place of study in the week 
preceding questionnaire completion, number of visits to shops or 
other indoor public places per week (quartiles 2, 3, 4 vs quartile 
1), alcohol consumption (15–21 vs 0 U/week), sleep duration (7 
or ≥9 vs 8 hours per night), raised body mass index (BMI) (>25.0 
vs ≤25.0 kg/m2) and history versus no history of BCG vaccination. 
The following factors associated with decreased odds of COVID- 19 
with p<0.10 after minimal adjustment: age ≥60 vs 16–29.99 years, 
education to college or postgraduate level versus primary/secondary 
level, shielding versus non- shielding, low- impact physical activity 
(≥2 vs 0 hours/week), presence versus absence of asthma diagnosis, 
presence versus absence of atopic disease (defined by atopic eczema/
dermatitis and/or hayfever/allergic rhinitis), use versus no use of 
systemic immunosuppressants, inhaled corticosteroids and bron-
chodilators (defined as β-2 adrenoreceptor agonists or anticholiner-
gics), higher intake of fruit and vegetables (top vs bottom quartiles) 
and use versus no use of vitamin D supplements.
All factors associating with test- confirmed COVID- 19 with 
p<0.10 in the minimally adjusted model were then assessed for 
collinearity: the resultant heat map (online supplemental figure 3) 
revealed a high degree of collinearity between the number of work-
ing- age adults in the household, multigenerational households and 
number of people per bedroom. Since household overcrowding (as 
indicated by number of people per bedroom) was deemed to relate 
most closely to SARS- CoV- 2 exposure risk from a clinical/epide-
miological perspective, the other two independent variables were 
excluded from the multivariable model.
Table 5 presents fully adjusted ORs for associations between 
potential risk factors for test- confirmed COVID- 19. The final multi-
variable model adjusted mutually for age, sex, duration of partici-
pation, test frequency, ethnicity, highest educational level attained, 
Index of Multiple Deprivation rank, household income, housing 
type, number of people per bedroom, presence of schoolchildren at 
home, presence of a dog in the household, shielding, visits to/from 
other households, visits to shops and other indoor places, travel to 
work or study, frontline worker status, low- impact physical activity, 
alcohol intake, BMI, history of asthma, history of atopic disease, use 
of systemic immunosuppressants, use of inhaled corticosteroids, use 
of bronchodilators, BCG vaccination status, intake of fruit, vegeta-
bles and salads, and intake of supplemental vitamin D. Increased 
odds of developing COVID- 19 were independently associated with 
Asian/Asian British versus white ethnicity (aOR 2.28, 95% CI 1.33 
to 3.91), household overcrowding (aOR per additional 0.5 people/
bedroom 1.26, 1.11 to 1.43), any versus no visits to/from other 
households in previous week (aOR 1.31, 1.06 to 1.62), number of 
visits to indoor public places (aOR per extra visit per week 1.05, 
1.02 to 1.09), frontline occupation outside health/social care versus 
no frontline occupation (aOR 1.49, 1.12 to 1.98), raised BMI (aOR 
1.50 (1.19 to 1.89) for BMI 25.0–30.0 kg/m2 and 1.39 (1.06 to 1.84) 
for BMI >30.0 kg/m2 versus BMI <25.0 kg/m2) and sleep >9 hours 
per night (aOR 1.29, 1.01 to 1.66). Lower odds of test- confirmed 
COVID- 19 were independently associated with history of atopic 
disease (aOR 0.75, 0.59 to 0.97) and taking systemic immunosup-
pressants (aOR 0.47, 0.22 to 0.99). Restricted cubic spline analysis 
showed non- linear associations between BMI (P for non- linearity 
0.009) and age (P for non- linearity 0.02) and incident test- defined 
COVID- 19 (figure 1).
We performed two sensitivity analyses to explore the robustness 
of the multivariable results. The first (online supplemental table 
4) excluded 3202 participants who received one or more doses 
of COVID- 19 vaccine before the date of the data download (5 
February 2021). The second (online supplemental table 5) excluded 
3813 participants who commenced vitamin D supplements after 
enrolment in the cohort due to participation in a clinical trial. 
Both analyses yielded similar findings to those presented above. An 
exploratory analysis to determine whether COVID- 19 risk differed 
for participants with atopic versus non- atopic asthma endotypes (as 
defined by the presence or absence of atopic eczema/dermatitis and/
or hayfever/allergic rhinitis) showed reduced odds of COVID- 19 
for participants with atopic asthma (aOR 0.62, 0.41 to 0.93), but 
not for those with non- atopic asthma (aOR 0.88, 0.60 to 1.30), as 
compared with participants without atopic disease or asthma. These 
effect estimates did not materially change after further adjustment 
for inhaled corticosteroids (online supplemental table 6).
We then proceeded to investigate determinants of symptom- 
defined probable COVID- 19, with casehood ascribed using an 
algorithm published by Menni et al.12 In the subset of 6035 COVI-
DENCE UK participants entering the prospective analysis who had 
one or more tests for COVID- 19 during the follow- up period, this 
case definition had sensitivity and specificity for test- confirmed 
COVID- 19 of 0.47 and 0.97, respectively, with an area under 
the receiver operating characteristic curve of 0.72 (95% CI 0.69 
to 0.74; online supplemental table 7). Potential risk factors associ-
ating with probable symptom- defined COVID- 19 with p<0.10 in a 
minimally adjusted model (ie, adjusting for age, sex and duration of 
participation) were included in the multivariable model presented 
in online supplemental table 8. Increased risk of probable symptom- 
defined COVID- 19 was independently associated with Asian/Asian 
British versus white ethnicity, housing type (having a mortgage vs 
home ownership), household overcrowding (>1.0 vs≤0.5 people 
per bedroom), health or social care occupation, use of cod liver oil 
supplements, poorer self- assessed general health, periodontitis and 
use of selective serotonin reuptake inhibitors, while lower risk of 
probable symptom- defined COVID- 19 was independently associ-
ated with greater age (age ≥50 vs 16–29.99 years).
DISCUSSION
In this large, prospective population- based study evaluating a 
diverse array of potential risk factors for developing COVID- 19, we 
found that Asian/Asian British ethnicity, household overcrowding, 
indoor social mixing, employment as a frontline worker outside 
of health and social care, and being overweight or obese were all 
independently associated with an increased risk of test- confirmed 
COVID- 19. Associations with household overcrowding and visits to 
indoor public places showed dose–response relationships, strength-
ening causal inference. History of atopic disease and use of systemic 
immunosuppressant medication were independently associated 
with decreased risk of test- positive disease. No statistically signifi-
cant independent associations with disease risk were seen for other 
factors investigated, including age, sex, diet, supplemental micronu-
trient intake, and other long- standing conditions and medications.
This study sheds new light on the degree of overlap between 
risk factors for developing COVID- 19 (irrespective of severity) 
versus risk factors for developing severe or fatal disease specifically. 
Our finding that people of Asian/Asian British ethnic origin are at 
increased risk of developing COVID- 19 is consistent with reports 
of increased susceptibility and disease severity in this group.4 7 18 
One limitation of previous studies investigating ethnic variation in 
COVID- 19 risk is that they did not adjust for behaviours influencing 
SARS- CoV- 2 exposure, such as visits to other households and indoor 
public places. In our study, increased risk of developing COVID- 19 
in people of Asian/Asian British ethnic origin was not explained by 
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such behaviours, nor by social deprivation, domestic overcrowding, 
occupation, BMI or comorbidities. There is therefore an urgent 
need for further research to investigate social and biological factors 
that might explain ethnic disparities in risk of developing COVID- 
19, including vitamin D deficiency.9 The association between raised 
BMI and increased susceptibility to COVID- 19 that we found is 
consistent with studies identifying obesity as a risk factor for both 
susceptibility to, and severe outcomes of, COVID- 19.4 19 20
By contrast, a number of established risk factors for severe and 
fatal disease, including older age, male sex and underlying condi-
tions such as diabetes, heart disease, COPD and hypertension, were 
not associated with risk of developing COVID- 19 in our study, 
where cases were predominantly mild (93.1% non- hospitalised). 
Our finding of no association between kidney disease and suscepti-
bility to COVID- 19 contrasts with that of de Lusignan et al,21 who 
reported such an association in a study that was conducted earlier 
in the UK pandemic when testing was limited to those with more 
severe COVID- 19 illness presenting to hospital. The bias resulting 
from focusing testing on more severe disease in that study may 
have contributed to the different findings in our study, which was 
conducted over a later period when testing was more widely avail-
able. In contrast with other studies,22 23 we found no association 
between intake of micronutrient supplements and protection against 
COVID- 19: this may reflect a false- negative result from our study 
(arising due to a relative lack of power to detect modest protec-
tive effects), or a false- positive result from other studies arising as 
a result of less rigorous adjustment for potential socioeconomic 
confounding.
In keeping with reports from the UK7 and elsewhere,8 we found 
younger age to be associated with increased risk of developing 
COVID- 19 in crude and minimally adjusted models. However, 
this association did not persist after adjustment for multiple poten-
tial confounders, including behaviours related to social mixing, 
suggesting that lower incidence of COVID- 19 in older adults in 
our study may be explained by reductions in social contact. We did 
not see a difference in disease risk for people with diabetes, heart 
disease or hypertension. While this contrasts with a study reporting 
lower prevalence of SARS- CoV- 2 seropositivity among people with 
these underlying conditions, that study did not adjust, as we did, 
for behaviours influencing exposure to infection.7 The only long- 
standing conditions associated with disease risk in our study were 
atopic diseases, which were associated with reduced risk of disease, 
particularly among those who also had asthma. This may reflect 
decreased expression of ACE2, the gene encoding the SARS- CoV- 2 
receptor, which has been reported in people with both high levels of 
allergic sensitisation and asthma.17
Our study has several strengths. COVIDENCE UK was set up 
with the specific purpose of investigating incident COVID- 19, 
and consequently our questionnaires were specifically designed 
to capture contemporaneous and granular detail on potential risk 
factors, including behaviours influencing risk of exposure to SARS- 
CoV- 2. Our finding that visits to other households and indoor 
public places were associated with increased risk of disease supports 
the case for restricting such activities as a public health strategy to 
control disease. Our low rates of loss to follow- up reflect the very 
high degree of participant engagement with the COVIDENCE UK 
Study. Our ability to identify episodes of milder disease affords poten-
tial insights into susceptibility factors as well as severity factors, and 
sets our study apart from long- established cohort studies in which 
assessment of risk factors may be temporally remote, and capture of 
outcomes is limited to events that are fatal or that precipitate hospi-
talisation. Our prospective design, coupled with censoring events 
occurring within 30 days of enrolment, minimises the potential for 
reverse causation to explain associations observed.
Our study also has limitations. Use of test- confirmed COVID- 19 
as our primary outcome may have resulted in underascertain-
ment of disease, particularly early in the pandemic (when testing 
capacity was particularly limited) and among people with less 
access to testing services; this might introduce collider bias.13 We 
addressed this limitation by including a secondary outcome of 
symptom- defined probable COVID- 19, which did not rely on 
access to testing. However, the lack of direct swabbing surveillance 
and reliance on results of routine testing that will usually have 
been prompted by incident symptoms may have led to underas-
certainment of asymptomatic SARS- CoV- 2 infection. A second 
issue relates to the self- selected nature of the cohort participants. 
Ethnic minorities, particularly people of black, African and Carib-
bean ethnic origin, were under- represented in the study; a lack of 
statistical power may explain why we did not confirm an increased 
risk of disease in these groups. People with limited internet access 
or with fewer digital skills are also less likely to have participated. 
However, lack of representativeness in a study population does 
not preclude identification of causal associations.24 Third, as with 
any observational study, we cannot exclude the possibility that 
the associations we report may be explained by residual and/or 
unmeasured confounding. We sought to minimise this by capture 
of, and mutual adjustment for, a comprehensive panel of poten-
tial confounders. Calculation of E- values enabled us to determine 
how likely it was that our main findings might be ‘explained away’ 
by unmeasured/unknown confounding factors. For example, for 
an unknown confounder to fully explain the association between 
frequent visits to shops/indoor places and COVID- 19 risk (OR 
2.63 comparing top vs bottom quartile of exposure), it would need 
to be associated with both the outcome and the exposure (above 
and beyond the measured confounders) by an OR of nearly 5 or 
more (table 5); weaker confounding could not explain away the 
association. In contrast, for the association between >9 hours’ sleep 
and COVID- 19 risk (OR 1.29) to be explained away, an unknown 
confounder would need to be associated with the exposure and 
outcome by an OR of at least 1.90; this effect estimate is compa-
rable with other risk factor associations we have found, and hence is 
more plausible for an unknown confounder. Accordingly, evidence 
for an unconfounded, causal association is considerably stronger for 
frequent visits to shops/indoor places than it is for prolonged sleep 
duration.
In conclusion, this population- based longitudinal study conducted 
in UK adults found that increased risk of developing COVID- 19 asso-
ciated independently with Asian/Asian British ethnicity, household 
overcrowding, visits to other households and other indoor public 
places, frontline occupation outside of health or social care, and 
increased BMI, after rigorous adjustment for multiple confounders. 
Atopic diseases, and especially atopic asthma, were associated with 
decreased risk. In contrast to studies investigating risk factors for 
severe disease, older age, male sex and other comorbidities were not 
associated with increased risk of developing COVID- 19.
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